| Structure | CCC=CCC=CCC=CCC(O)C=CC1C(O)CC(=O)C1CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C InChI=1S/C29H45NO7/c1-5-6-7-8-9-10-11-12-13-14-22(31)15-16-24-25(27(33)20-26(24)32)17-18-29(36)37-23(19-28(34)35)21-30(2,3)4/h6-7,9-10,12-13,15-16,22-26,31-32H,5,8,11,14,17-21H2,1-4H3 |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross Sections| Predictor | Adduct Type | CCS Value (Å2) | Reference |
|---|
| DeepCCS | [M+H]+ | 218.994 | 30932474 | | DeepCCS | [M-H]- | 215.697 | 30932474 | | DeepCCS | [M-2H]- | 249.948 | 30932474 | | DeepCCS | [M+Na]+ | 226.324 | 30932474 |
Predicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. | 4.38 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 16.398 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.09 minutes | 32390414 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2720.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 181.8 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 218.3 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 183.3 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 181.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 675.2 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 482.6 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 565.2 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1605.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 558.8 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1888.5 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 402.8 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 450.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 352.5 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 128.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatized| Metabolite | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine | CCC=CCC=CCC=CCC(O)C=CC1C(O)CC(=O)C1CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C | 4335.0 | Standard polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine | CCC=CCC=CCC=CCC(O)C=CC1C(O)CC(=O)C1CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C | 2825.2 | Standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine | CCC=CCC=CCC=CCC(O)C=CC1C(O)CC(=O)C1CCC(=O)OC(CC([O-])=O)C[N+](C)(C)C | 3626.1 | Semi standard non polar | 33892256 |
Derivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(O)CC(=O)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3721.3 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TMS,isomer #2 | CCC=CCC=CCC=CCC(O)C=CC1C(O[Si](C)(C)C)CC(=O)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3693.4 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TMS,isomer #3 | CCC=CCC=CCC=CCC(O)C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O | 3665.4 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TMS,isomer #4 | CCC=CCC=CCC=CCC(O)C=CC1C(O)C=C(O[Si](C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3677.4 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C)CC(=O)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3654.5 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O)O[Si](C)(C)C | 3658.9 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TMS,isomer #3 | CCC=CCC=CCC=CCC(C=CC1C(O)C=C(O[Si](C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3631.6 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TMS,isomer #4 | CCC=CCC=CCC=CCC(O)C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C | 3675.0 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TMS,isomer #5 | CCC=CCC=CCC=CCC(O)C=CC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3662.4 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C)O[Si](C)(C)C | 3627.7 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C)O[Si](C)(C)C | 3535.2 | Standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C)CC1O[Si](C)(C)C)O[Si](C)(C)C | 4010.7 | Standard polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3592.2 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 3465.6 | Standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C)C=C(O[Si](C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C | 4003.3 | Standard polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TBDMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(O)CC(=O)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 3960.8 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TBDMS,isomer #2 | CCC=CCC=CCC=CCC(O)C=CC1C(O[Si](C)(C)C(C)(C)C)CC(=O)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3914.7 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TBDMS,isomer #3 | CCC=CCC=CCC=CCC(O)C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O | 3928.4 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,1TBDMS,isomer #4 | CCC=CCC=CCC=CCC(O)C=CC1C(O)C=C(O[Si](C)(C)C(C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 3914.5 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TBDMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C(C)(C)C)CC(=O)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4085.3 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TBDMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O)O[Si](C)(C)C(C)(C)C | 4115.4 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TBDMS,isomer #3 | CCC=CCC=CCC=CCC(C=CC1C(O)C=C(O[Si](C)(C)C(C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4081.6 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TBDMS,isomer #4 | CCC=CCC=CCC=CCC(O)C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C | 4115.3 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,2TBDMS,isomer #5 | CCC=CCC=CCC=CCC(O)C=CC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | 4111.3 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TBDMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4220.8 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TBDMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4027.0 | Standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TBDMS,isomer #1 | CCC=CCC=CCC=CCC(C=CC1C(CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)=C(O[Si](C)(C)C(C)(C)C)CC1O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4034.3 | Standard polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TBDMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4191.0 | Semi standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TBDMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 3922.0 | Standard non polar | 33892256 | | 3-[(1S,2R,3R)-3-Hydroxy-2-[(1E,3S,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl]-5-oxocyclopentyl]propanoylcarnitine,3TBDMS,isomer #2 | CCC=CCC=CCC=CCC(C=CC1C(O[Si](C)(C)C(C)(C)C)C=C(O[Si](C)(C)C(C)(C)C)C1CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C)O[Si](C)(C)C(C)(C)C | 4036.5 | Standard polar | 33892256 |
|
|---|